Ligand Reports Q4 Revenue of $59.666M, Exceeding Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy LGND?
Reports Q4 revenue $59.666M, consensus $55.59M. "We delivered strong fourth quarter results, exceeding our initial full-year adjusted EPS guidance by approximately 30%. This growth was driven by better-than-expected performance across several products in our royalty portfolio, including the successful out-licensing and partner launch of Zelsuvmi. These results highlight the strength of our team and their ability to invest in high-value assets that address significant unmet clinical needs. As we enter 2026, we have a strong balance sheet and are well positioned to execute on our broad pipeline of investment opportunities that we believe position us to continue driving growth and creating long-term shareholder value," said Todd Davis, CEO of Ligand.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LGND?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LGND
Wall Street analysts forecast LGND stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 198.310
Low
220.00
Averages
237.20
High
270.00
Current: 198.310
Low
220.00
Averages
237.20
High
270.00
About LGND
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ligand Pharmaceuticals Reports Strong Q4 2025 Earnings and Growth Outlook
- Exceptional Financial Performance: Ligand Pharmaceuticals exceeded its original 2025 adjusted EPS guidance by over 30%, reporting total revenue of $268 million, a 60% increase year-over-year, showcasing the company's strong market performance and enhanced profitability.
- Royalty Revenue Growth: Royalty revenue reached $161 million in 2025, up 48% year-over-year, primarily driven by successful launches of FILSPARI, Ohtuvayre, and CAPVAXIVE, indicating effective strategies in new product development and market penetration.
- Optimistic Future Outlook: Management expects adjusted EPS for 2026 to be between $8 and $9, with royalty revenue projected to grow by 32%, reflecting confidence in future revenue growth and a strategic focus on continued investment in new products.
- Portfolio Management Upgrade: The company has launched a more systematic portfolio management process aimed at actively driving value across partnerships, further enhancing its competitive position and market standing in the biopharmaceutical sector.
See More
Ligand Pharmaceuticals Reports Strong 2025 Financial Performance with 48% Royalty Revenue Growth
- Financial Performance Growth: Ligand Pharmaceuticals reported total revenues of $268.1 million for 2025, a 60% increase from $167.1 million in 2024, with royalty revenue rising 45% to $161.0 million, showcasing the company's success in investing in high-value assets.
- Strong Fourth Quarter Results: In Q4 2025, revenues reached $59.7 million, up 39% from $42.8 million in Q4 2024, primarily driven by increased sales of products from Travere Therapeutics and Merck, further solidifying Ligand's market position.
- Adjusted Net Income Surge: The adjusted net income for Q4 2025 was $42.7 million, or $2.02 per diluted share, significantly up from $25.2 million and $1.27 per diluted share in Q4 2024, reflecting robust performance in royalty revenue growth.
- 2026 Financial Guidance Reaffirmed: Ligand expects total revenues for 2026 to range between $245 million and $285 million, with adjusted earnings per diluted share projected at $8.00 to $9.00, demonstrating confidence in future growth and the sustainability of its strategic planning.
See More
Ligand Pharmaceuticals Releases 2026 Financial Guidance
- Earnings Beat: Ligand Pharmaceuticals reported a Q4 non-GAAP EPS of $2.02, exceeding expectations by $0.52, indicating strong profitability that is likely to positively impact stock performance.
- Significant Revenue Growth: The company achieved Q4 revenue of $59.7 million, a 39.5% year-over-year increase, surpassing market expectations by $4.11 million, demonstrating robust demand and sales that bolster investor confidence.
- 2026 Financial Guidance Reaffirmed: Ligand reaffirmed its 2026 financial guidance, projecting adjusted earnings per diluted share between $8.00 and $9.00, reflecting confidence in future profitability that may attract more investor interest.
- Diverse Revenue Streams: The company anticipates 2026 royalty revenue between $200 million and $225 million, Captisol sales between $35 million and $40 million, and contract revenue between $10 million and $20 million, leading to total revenue expectations of $245 million to $285 million, showcasing a diverse and stable revenue structure.
See More
Ligand Pharmaceuticals Set to Announce Q4 Earnings on February 26
- Earnings Announcement Schedule: Ligand Pharmaceuticals is set to release its Q4 2023 earnings report on February 26 before market open, with consensus EPS estimated at $1.50, reflecting an 18.1% year-over-year increase, and revenue expected at $55.59 million, up 29.9%, indicating sustained growth potential in financial performance.
- Performance Beat Record: Over the past two years, Ligand has surpassed EPS estimates 88% of the time and revenue estimates 100% of the time, showcasing the company's strong performance against market analyst expectations, which bolsters investor confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen four upward revisions and one downward revision, while revenue estimates experienced two upward and two downward revisions, reflecting varying market perceptions of the company's future performance that could influence investor decisions.
- Increased Market Attention: With Citi initiating a “Buy” rating on Ligand Pharmaceuticals and growing interest in the 2026 outlook, investor confidence in the company's future growth potential and valuation may further strengthen.
See More
S&P 500 and Dow Reverse Gains as Nasdaq Narrows Upturn
- Market Volatility: On Wednesday, the S&P 500 and Dow reversed from their highs, indicating a shift in market sentiment that could influence short-term investor decisions.
- Nasdaq Performance: Although the Nasdaq index initially gained, it ultimately narrowed its gains, reflecting the volatility of tech stocks and the uncertainty in the market.
- Buy Signals: Eli Lilly and Google flashed buy signals, potentially attracting investor interest in these companies' future growth prospects, especially in the current market environment.
- Investor Sentiment: The overall market reversal may lead investors to reassess their risk appetite, thereby affecting capital flows and market dynamics.
See More
S&P 500 and Dow Retreat from Highs, Eli Lilly and Google Flash Buy Signals
- Market Volatility: On Wednesday, the S&P 500 and Dow retreated from their highs, indicating a shift in market sentiment that could influence short-term investor decisions and risk appetite.
- Nasdaq Performance: Although the Nasdaq index pared gains, it still shows potential for growth, suggesting that volatility in tech stocks may provide short-term trading opportunities for investors.
- Buy Signals: Stocks of Eli Lilly and Google flashed buy signals, potentially attracting investor attention to the growth prospects of these companies in their respective sectors, which could drive their stock prices higher.
- Investor Strategy Adjustment: The market fluctuations and buy signals may prompt investors to reassess their portfolios, particularly in the current economic environment, seeking more promising investment opportunities.
See More
Ligand Pharmaceuticals Reports Strong Q4 2025 Earnings and Growth Outlook
- Exceptional Financial Performance: Ligand Pharmaceuticals exceeded its original 2025 adjusted EPS guidance by over 30%, reporting total revenue of $268 million, a 60% increase year-over-year, showcasing the company's strong market performance and enhanced profitability.
- Royalty Revenue Growth: Royalty revenue reached $161 million in 2025, up 48% year-over-year, primarily driven by successful launches of FILSPARI, Ohtuvayre, and CAPVAXIVE, indicating effective strategies in new product development and market penetration.
- Optimistic Future Outlook: Management expects adjusted EPS for 2026 to be between $8 and $9, with royalty revenue projected to grow by 32%, reflecting confidence in future revenue growth and a strategic focus on continued investment in new products.
- Portfolio Management Upgrade: The company has launched a more systematic portfolio management process aimed at actively driving value across partnerships, further enhancing its competitive position and market standing in the biopharmaceutical sector.
See More
Ligand Pharmaceuticals Reports Strong 2025 Financial Performance with 48% Royalty Revenue Growth
- Financial Performance Growth: Ligand Pharmaceuticals reported total revenues of $268.1 million for 2025, a 60% increase from $167.1 million in 2024, with royalty revenue rising 45% to $161.0 million, showcasing the company's success in investing in high-value assets.
- Strong Fourth Quarter Results: In Q4 2025, revenues reached $59.7 million, up 39% from $42.8 million in Q4 2024, primarily driven by increased sales of products from Travere Therapeutics and Merck, further solidifying Ligand's market position.
- Adjusted Net Income Surge: The adjusted net income for Q4 2025 was $42.7 million, or $2.02 per diluted share, significantly up from $25.2 million and $1.27 per diluted share in Q4 2024, reflecting robust performance in royalty revenue growth.
- 2026 Financial Guidance Reaffirmed: Ligand expects total revenues for 2026 to range between $245 million and $285 million, with adjusted earnings per diluted share projected at $8.00 to $9.00, demonstrating confidence in future growth and the sustainability of its strategic planning.
See More
Ligand Pharmaceuticals Releases 2026 Financial Guidance
- Earnings Beat: Ligand Pharmaceuticals reported a Q4 non-GAAP EPS of $2.02, exceeding expectations by $0.52, indicating strong profitability that is likely to positively impact stock performance.
- Significant Revenue Growth: The company achieved Q4 revenue of $59.7 million, a 39.5% year-over-year increase, surpassing market expectations by $4.11 million, demonstrating robust demand and sales that bolster investor confidence.
- 2026 Financial Guidance Reaffirmed: Ligand reaffirmed its 2026 financial guidance, projecting adjusted earnings per diluted share between $8.00 and $9.00, reflecting confidence in future profitability that may attract more investor interest.
- Diverse Revenue Streams: The company anticipates 2026 royalty revenue between $200 million and $225 million, Captisol sales between $35 million and $40 million, and contract revenue between $10 million and $20 million, leading to total revenue expectations of $245 million to $285 million, showcasing a diverse and stable revenue structure.
See More
Ligand Pharmaceuticals Set to Announce Q4 Earnings on February 26
- Earnings Announcement Schedule: Ligand Pharmaceuticals is set to release its Q4 2023 earnings report on February 26 before market open, with consensus EPS estimated at $1.50, reflecting an 18.1% year-over-year increase, and revenue expected at $55.59 million, up 29.9%, indicating sustained growth potential in financial performance.
- Performance Beat Record: Over the past two years, Ligand has surpassed EPS estimates 88% of the time and revenue estimates 100% of the time, showcasing the company's strong performance against market analyst expectations, which bolsters investor confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen four upward revisions and one downward revision, while revenue estimates experienced two upward and two downward revisions, reflecting varying market perceptions of the company's future performance that could influence investor decisions.
- Increased Market Attention: With Citi initiating a “Buy” rating on Ligand Pharmaceuticals and growing interest in the 2026 outlook, investor confidence in the company's future growth potential and valuation may further strengthen.
See More
S&P 500 and Dow Reverse Gains as Nasdaq Narrows Upturn
- Market Volatility: On Wednesday, the S&P 500 and Dow reversed from their highs, indicating a shift in market sentiment that could influence short-term investor decisions.
- Nasdaq Performance: Although the Nasdaq index initially gained, it ultimately narrowed its gains, reflecting the volatility of tech stocks and the uncertainty in the market.
- Buy Signals: Eli Lilly and Google flashed buy signals, potentially attracting investor interest in these companies' future growth prospects, especially in the current market environment.
- Investor Sentiment: The overall market reversal may lead investors to reassess their risk appetite, thereby affecting capital flows and market dynamics.
See More
S&P 500 and Dow Retreat from Highs, Eli Lilly and Google Flash Buy Signals
- Market Volatility: On Wednesday, the S&P 500 and Dow retreated from their highs, indicating a shift in market sentiment that could influence short-term investor decisions and risk appetite.
- Nasdaq Performance: Although the Nasdaq index pared gains, it still shows potential for growth, suggesting that volatility in tech stocks may provide short-term trading opportunities for investors.
- Buy Signals: Stocks of Eli Lilly and Google flashed buy signals, potentially attracting investor attention to the growth prospects of these companies in their respective sectors, which could drive their stock prices higher.
- Investor Strategy Adjustment: The market fluctuations and buy signals may prompt investors to reassess their portfolios, particularly in the current economic environment, seeking more promising investment opportunities.
See More
